Document Detail

Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A.
MedLine Citation:
PMID:  2712549     Owner:  NLM     Status:  MEDLINE    
The efficacy and safety of prophylactic low dose amantadine hydrochloride was assessed in two double-blind, placebo-controlled, randomized studies. In a study of 476 subjects aged 18 to 55 years, adverse reactions were not significantly different between the group receiving 100 mg/day amantadine and the placebo group but significantly greater in the group given 200 mg/day (P less than 0.009). The influenza attack rate in this study was too low to assess efficacy. In an experimental challenge study of influenza A/Beth/1/85 in 78 subjects of similar age the prophylactic administration of 50 mg, 100 mg or 200 mg/day doses of amantadine were more effective than placebo in preventing influenza illness (P less than 0.02, 66, 74 and 82% protection, respectively), and in suppressing viral replication (P = 0.02). There was no significant difference between amantadine groups in influenza illness or viral shedding. Compared with the placebo group the 100 and 200 mg amantadine groups showed a significant decrease in infection rate (100 mg: 40% protection: P = 0.012; 200 mg: 32% protection: P = 0.045) whereas the 50 mg group did not (20% protection: P = 0.187). These results suggest that 100 mg/day of amantadine will reduce toxicity but maintain the prophylactic efficacy seen with 200 mg/day.
P D Reuman; D I Bernstein; M C Keefer; E C Young; J R Sherwood; G M Schiff
Related Documents :
24744819 - Distribution of the radiation dose in multislice computer tomography of the chest - pha...
24651939 - Dosimetric evaluation of a 256-slice computed tomography scanner.
23274819 - Measurements of indoor radon concentration levels in dwellings in bethlehem, palestine.
22927649 - Determination of radon level and radon effective dose rate using ssntd in dwellings in ...
24385889 - Metal concentrations in cosmetics commonly used in nigeria.
23127069 - A real-time in vivo dosimetric verification method for high-dose rate intracavitary bra...
2412049 - Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
20733579 - Phase i trial of cyt997, a novel cytotoxic and vascular-disrupting agent.
10638559 - Twenty-four-hour intragastric ph: tolerance within 5 days of continuous ranitidine admi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Antiviral research     Volume:  11     ISSN:  0166-3542     ISO Abbreviation:  Antiviral Res.     Publication Date:  1989 Feb 
Date Detail:
Created Date:  1989-06-07     Completed Date:  1989-06-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8109699     Medline TA:  Antiviral Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  27-40     Citation Subset:  IM    
James N. Gamble Institute of Medical Research, Cincinnati, Ohio 45219.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amantadine / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Double-Blind Method
Influenza A virus / drug effects,  isolation & purification
Influenza, Human / prevention & control*
Middle Aged
Random Allocation
Time Factors
Virus Replication / drug effects
Reg. No./Substance:
0/Placebos; 768-94-5/Amantadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sucralfate reduces the gastrointestinal absorption of norfloxacin.
Next Document:  Antiviral activity of tiazofurine against barley stripe mosaic virus.